Yichao Wang

Dr. Yichao Wang

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
YCYou Cheng
You Cheng
ZLZhaoyun Li
Zhaoyun Li
JXJiaogui Xie
Jiaogui Xie
PWPan Wang
Pan Wang
JZJie Zhu
Jie Zhu
YWYichao Wang
Yichao Wang

25 July 2022 in Pharmacological Research
Verified
Journal Article
Closed access
CLChunping Liu
Chunping Liu
DHDongyue He
Dongyue He
LLLongmei Li
Longmei Li
SZShihui Zhang
Shihui Zhang
LWLei Wang
Lei Wang
YWYichao Wang
Yichao Wang

2 February 2024 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
QLQuanshi Lin
Quanshi Lin
YWYichao Wang
Yichao Wang
LWLinlin Wang
Linlin Wang
ZFZhijin Fan
Zhijin Fan

21 June 2022 in International Journal of Medical Sciences
Verified
Journal Article
Open access
XHXinwei Han
Xinwei Han
JMJinggang Mo
Jinggang Mo
YYYingmei Yang
Yingmei Yang
YWYichao Wang
Yichao Wang
HLHongsheng Lu
Hongsheng Lu
Breast cancer remains a worldwide public health issue. LncRNA and autophagy respectively or simultaneously, get involved in cellular and molecular processes of many different cancers, including genesis, metastasis, and deterioration of breast cancer and other malignant tumors. In this review, relevant studies have been summarized, and we have found that lncRNA-mediated autophagy in luminal A breast cancer, luminal B breast cancer, HER-2 positive breast cancer, and basal-like breast cancer may play an important role in mediating drug resistance sensitivity. LncRNAs target genes and affect different signaling pathways to a complex network, which attenuates the occurrence and development of primary breast cancer by coordinating autophagy. Abnormal expression of LncRNA may lead to dysregulation of autophagy, resulting in tumor genesis, expansion, and resistance to anti-tumor therapy. Targeting specific lncRNAs for autophagy regulation may conduct as a bio-marker for reliable diagnosis and prognosis treatment of breast cancer or provide a promising therapeutic strategy.

30 August 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
LWLing Wu
Ling Wu
HLHongsheng Lu
Hongsheng Lu
YPYin Pan
Yin Pan
CLChen Liu
Chen Liu
JWJinyan Wang
Jinyan Wang
YWYichao Wang
Yichao Wang
Pyroptosis is a brand-new category of programmed cell death (PCD) that is brought on by multitudinous inflammasomes, which can recognize several stimuli to pilot the cleavage of and activate inflammatory cytokines like IL-18 and IL-1β is believed to have dual effects on the development of multiple cancers including breast cancer. However, pyroptosis has different effects on cancers depending on the type of tissues and their distinct heredity. Recently, the association between pyroptosis and breast cancer has received more and more attention, and it is thought that inducing pyroptosis could be used as a cancer treatment option. In addition, a great deal of evidence accumulating over the past decades has evinced the crosstalk between pyroptosis and tumor immunological therapy. Thus, a comprehensive summary combining the function of pyroptosis in breast cancer and antitumor immunity is imperative. We portray the prevalent knowledge of the multidimensional roles of pyroptosis in cancer and summarize the pyroptosis in breast cancer principally. Moreover, we elucidate the influence of inflammasomes and pyroptosis-produced cytokines on the tumor microenvironment (TME) of breast cancer. Taken together, we aim to provide a clue to harness pyroptosis rationally and apply it to augment immunotherapy efficiency for breast cancer.

8 March 2023 in Analytica Chimica Acta
Verified
Journal Article
Closed access
SZSiqi Zhang
Siqi Zhang
HSHuahao Shao
Huahao Shao
KLKai-Bin Li
Kai-Bin Li
WSWei Shi
Wei Shi
YWYichao Wang
Yichao Wang
JMJinggang Mo
Jinggang Mo